← All trials
NCT06422039
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2024
- Primary completion
- Jun 1, 2024
- Completion date
- Jun 15, 2024
- First posted
- May 20, 2024
- Last posted
- May 20, 2024
- Enrollment
- 18
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.